Cargando…
Engineered botulinum neurotoxin B with improved efficacy for targeting human receptors
Botulinum neurotoxin B is a Food and Drug Administration-approved therapeutic toxin. However, it has lower binding affinity toward the human version of its major receptor, synaptotagmin II (h-Syt II), compared to mouse Syt II, because of a residue difference. Increasing the binding affinity to h-Syt...
Autores principales: | Tao, Liang, Peng, Lisheng, Berntsson, Ronnie P.-A., Liu, Sai Man, Park, SunHyun, Yu, Feifan, Boone, Christopher, Palan, Shilpa, Beard, Matthew, Chabrier, Pierre-Etienne, Stenmark, Pål, Krupp, Johannes, Dong, Min |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5495808/ https://www.ncbi.nlm.nih.gov/pubmed/28674381 http://dx.doi.org/10.1038/s41467-017-00064-y |
Ejemplares similares
-
Structure of dual receptor binding to botulinum neurotoxin
B
por: Berntsson, Ronnie P-A, et al.
Publicado: (2013) -
Engineered botulinum neurotoxin B with improved binding to human receptors has enhanced efficacy in preclinical models
por: Elliott, Mark, et al.
Publicado: (2019) -
Augmentation of VAMP-catalytic activity of botulinum neurotoxin serotype B does not result in increased potency in physiological systems
por: Elliott, Mark, et al.
Publicado: (2017) -
Structural basis for the unique ganglioside and cell membrane recognition mechanism of botulinum neurotoxin DC
por: Zhang, Sicai, et al.
Publicado: (2017) -
Mechanism of Ganglioside Receptor Recognition by Botulinum Neurotoxin Serotype E
por: Masuyer, Geoffrey, et al.
Publicado: (2021)